Use of Tareg in Children
Children with an abnormality in the functioning of the kidney/liver,
fever, or
dehydration are at an increased risk when using Tareg. Tareg should not be used in children with
creatinine clearance less than 30 ml/min, severe abnormal functioning of the liver, and obstruction of bile flow (
cholestasis, and obstructive biliary disorders). Monitoring of the functioning of the kidney and
potassium levels should be considered. Also, patients with abnormal functioning of the kidney should not use angiotensin II receptor blocker or angiotensin converting enzyme inhibitors with aliskiren.
Dual Blockade of the Renin-Angiotensin-Aldosterone System
Patients using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, ramipril or aliskiren are at an increased risk while using Tareg. Such patients are at an increased risk of low blood pressure, increased
potassium level, and decreased functioning of the kidneys. Avoid the combined use of angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, ramipril or aliskiren. Proper monitoring of the functioning of the kidney, blood pressure, and electrolytes should be considered.
Swelling in the Lower Layer of the Skin
Patients with a history of swelling of the lower layer of skin or taking Tareg are at an increased risk when using Tareg. These patients may experience swelling of the larynx, lips, face, tongue, pharynx, an opening between the vocal folds (glottis), and airway obstruction. Tareg should be discontinued immediately on the occurrence of swelling of the lower layer of the skin and should not be started again.
Abnormality in the Functioning of the Liver
Patients with an abnormality in the functioning of the liver or in the bile flow (
cholestasis) are at increased risk when using Tareg. Take necessary precautions in such patients.
Heart Problems
Precaution should be taken in patients with obstruction in the blood flow of the heart (aortic and mitral valve
stenosis) and thickening of the heart muscles (Hypertrophic
cardiomyopathy).
Increased Production of Aldosterone
These patients do not respond to blood pressure lowering drugs. Tareg should not be used in patients with increased production of aldosterone (primary
hyperaldosteronism).
Increased Levels of Potassium
Patients with heart failure or abnormality in the functioning of the kidney taking Tareg are at increased risk. These patients may experience increased levels of
potassium in the blood. Discontinuation of Tareg or dose reduction should be considered in such patients. Patients should not use Tareg with potassium-sparing
diuretics, potassium supplements, agents increasing potassium levels (heparin), and
salt substitutes containing potassium.
Abnormality in the Functioning of the Kidney
Patients with an abnormality in the functioning of the kidney, narrowing of kidney arteries (renal artery
stenosis), heart failure or volume-depleted patients are at increased risk when using Tareg. Use of Tareg may cause kidney failure in these patients. Precaution along with monitoring should be considered in such patients. Tareg should not be used with angiotensin-converting enzyme inhibitors and aliskiren in patients with an abnormality in the functioning of the kidney.
Low Blood Pressure
Patients with high blood pressure, heart diseases, and
sodium or volume-depleted patients taking Tareg are at increased risk. Symptomatic low blood pressure, increased level of
potassium and decreased functioning of the kidney, and fatality may occur in these patients when taking Tareg alone or in combination with angiotensin-converting enzyme inhibitors. The condition of the patient should be corrected and monitored before starting Tareg therapy. Take necessary precautions while starting Tareg therapy. On the occurrence of severe low blood pressure, the patient should be placed in the supine position or infusion of normal saline in the veins should be given to the patients.
Increased Mortality in Infants
A fetus is at increased risk when pregnant women use this medicine. The use of Tareg during the second and third trimesters of
pregnancy may lead to fetal and neonatal injury, including reduced functioning of the kidney, low blood pressure, deficiency of amniotic fluid, abnormalities of the skull and lung, insufficiency to produce urine, kidney failure, or other fatal conditions. Discontinue the use of Tareg immediately after diagnosis of pregnancy.
Genetic Problems
This medicine should not be used in patients with rare genetic problems of galactose intolerance, the Lapp lactase deficiency or disturbed absorption of glucose-galactose.
Lecithin
Tareg should not be used in patients allergic to peanut or soya.